tbuckley/cabot-search huggingface dataset:
Beyond Anthrax
Authors: R. Steven Tharratt
Journal: Annals of Internal Medicine (2009)

Medical Writings: Book Notes1 December 2009Beyond AnthraxR. Steven Tharratt, MD, MPVMR. Steven Tharratt, MD, MPVMFrom University of California, Davis, and California Emergency Medical Services Authority, Davis, California.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-151-11-200912010-00030 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Lutwick LI, Lutwick SM, eds. 374 pages. Totowa, NJ: Humana Pr; 2009. $149.00. ISBN 9781588294388. Order at www.springer.com/humana+press.Field of medicine: Public health and infectious diseases.Format: Hardcover book.Audience: Students, clinicians, and epidemiologists desiring a broad overview, including public health implications, of infectious agents and toxins that can be used as weapons in a biological attack.Purpose: The book is “meant as a primer … on a variety of agents, organisms, or toxins, which are generally considered at the forefront of potential use in a biological attack from a rogue nation or radical group.”Content: This edited volume (with ... Author, Article, and Disclosure InformationAffiliations: From University of California, Davis, and California Emergency Medical Services Authority, Davis, California. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 December 2009Volume 151, Issue 11Page: 828KeywordsAnthraxClinical microbiologyEmergency medical servicesEpidemiologyFoodInfectious diseasesMicrobiologyPrevention, policy, and public healthToxins ePublished: 1 December 2009 Issue Published: 1 December 2009 Copyright & PermissionsCopyright © 2009 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Eponyms
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
FRANCE
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Clinically silent primary adrenal lymphoma: A case report and review of the literature
Authors: Jun Wang, Nora C.J. Sun, Richard Renslo, Chan‐Chou Chuang, Hassan J. Tabbarah, Luciano Barajas, Samuel W. French
Journal: American Journal of Hematology (1998)

Primary adrenal lymphoma (PAL) is extremely uncommon. We describe a case of clinically silent non-Hodgkin's B-cell lymphoma of diffuse large cell type with exclusive left adrenal localization. The tumor was discovered by computed tomography (CT) as a 2.5-cm dense mass and diagnosed at autopsy. Literature concerning this unusual neoplasm is reviewed. During the early stage, particularly when the lesion is small, PAL is likely to be missed. This unusual entity should be included in the differential diagnosis of adrenal masses so that early diagnosis may be made and intervention might dramatically affect the clinical outcome. Am. J. Hematol. 58:130–136, 1998. © 1998 Wiley-Liss, Inc.
Error in Conflicts of Interest Disclosures
Authors: Sana Al-Khatib, Gregg Fonarow, Gillian Sanders
Journal: JAMA Cardiology (2017)

Christopher M. Cook, MBBS; Ricardo Petraco, MD, PhD; Matthew J. Shun-Shin, MBBS; Yousif Ahmad, MBBS; Sukhjinder Nijjer, MBChB; Rasha Al-Lamee, MBBS; Yuetsu Kikuta, MD; Yasutsugu Shiono, MD; Jamil Mayet, MBChB, MD, MBA; Darrel P. Francis, MB, BChir, MA, MD; Sayan Sen, MBBS, PhD; Justin E. Davies, MBBS, PhD
Contents
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
AIDS drug development, availability intensify
Authors: M. F. Goldsmith
Journal: JAMA (1989)

RECENT ACTIONS by federal health officials deliver on promises made in Montreal at the Fifth International Conference on Acquired Immunodeficiency Syndrome (AIDS) to speed up development, clinical trials, and availability of drugs to combat human immunodeficiency virus (HIV) disease. A month ago, the Food and Drug Administration (FDA) approved for marketing ganciclovir, produced by Syntex Corporation, Palo Alto, Calif, which is used to treat cytomegalovirus retinitis. The agency also gave the status of "investigational new drug for treatment"—thus allowing expanded premarket distribution—to recombinant human erythropoietin used to treat AIDS-associated anemia, produced by Ortho Pharmaceutical Corporation, Raritan, NJ. Ortho has announced that the company will provide the drug free during testing to patients who are anemic either as a result of HIV infection or because of the effects of taking zidovudine, or AZT. Two weeks earlier, the FDA approved for marketing aerosolized pentamidine (made by Lyphomed Inc, Rosemont, Ill) as prophylaxis
THE INTELLECTUAL LIFE AND THE PHYSICIAN
Journal: JAMA (2010)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pneumococcal Disease and HIV Infection
Authors: Edward H. Janoff
Journal: Annals of Internal Medicine (1993)

Letters1 March 1993Pneumococcal Disease and HIV InfectionEdward H. Janoff, MDEdward H. Janoff, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-118-5-199303010-00015 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:The important work of Gilks suggests that the epidemiology and clinical spectrum of pneumococcal disease in HIV-infected patients is strikingly similar in the United States and Kenya. In both locations, HIV-infected patients comprise a significant proportion of patients with pneumococcal bacteremia, and Streptococcus pneumoniae is among the most common causes of bacteremia and pneumonia in patients with HIV. Moreover, rates of recurrent disease (relapse or reinfection) may be high, whereas mortality is often lower than among bacteremic, HIV-seronegative patients. Delineation of associated risk factors in Africa such as sickle cell disease, malnutrition, or malaria would be of interest. ...References1. American College of Physicians. Guide for Adult Immunization. 2d ed. Philadelphia: American College of Physicians; 1990. Google Scholar2. Breen EC, Rezae AR, Nakajima K, Beall GN, Mitsuyasu RT, Hirano T, Kishimoto T, Martinez-Maza O. Infection with HIV is associated with elevated IL-6 levels and production. J Immunol. 1990; 144:480-4. Google Scholar3. Janoff EN, O'Brien J, Thompson P, Ehret J, Meiklejohn G, Duvall G, et al. Streptococcus pneumoniae colonization and bacteremia among persons with HIV infection. J Infect Dis. 1993; 167:49-56. Google Scholar Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 March 1993Volume 118, Issue 5Page: 393-394KeywordsBacteremiaC-reactive proteinsChildrenClinical epidemiologyCytokinesHIVHIV infectionsInfectious diseasesMortalityPneumonia ePublished: 15 August 2000 Issue Published: 1 March 1993 Copyright & PermissionsCopyright © 1993 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Clarification of Reporting of Conflicts of Interest
Journal: JAMA (2019)

Pierre-Francois Laterre, MD; Scott M. Berry, PhD; Allan Blemings, MS; Jan E. Carlsen, MD; Bruno François, MD; Todd Graves, PhD; Karsten Jacobsen, MD; Roger J. Lewis, MD, PhD; Steven M. Opal, MD; Anders Perner, MD, PhD; Peter Pickkers, MD, PhD; James A. Russell, MD; Nis A. Windeløv, MD, PhD; Donald M. Yealy, MD; Pierre Asfar, MD; Morten H. Bestle, MD, PhD; Grégoire Muller, MD; Cédric Bruel, MD; Noëlle Brulé, MD; Johan Decruyenaere, MD; Alain-Michel Dive, MD, PhD; Thierry Dugernier, MD, PhD; Kenneth Krell, MD; Jean-Yves Lefrant, MD; Bruno Megarbane, MD, PhD; Emmanuelle Mercier, MD; Jean-Paul Mira, MD, PhD; Jean-Pierre Quenot, MD; Bodil Steen Rasmussen, MD, PhD; Hans-Christian Thorsen-Meyer, MD; Margot Vander Laenen, MD; Marianne Lauridsen Vang, MD; Philippe Vignon, MD, PhD; Isabelle Vinatier, MD; Sine Wichmann, MD, PhD; Xavier Wittebole, MD; Anne Louise Kjølbye, MS, PhD; Derek C. Angus, MD, MPH; for the SEPSIS-ACT Investigators
Difficult questions at Glasgow.
Journal: BMJ (1977)

picture of hyperthyroidism would usually be considered a reasonably strong point against the diagnosis, especially in young patients, and the finding of a low thyroid uptake of radioactive iodine would be accepted by most people as evidence justifying exclusion of the disease.In such circum- stances the physician should think of unusual causes of hyperthyroidism-thyrotoxicosis factitia, the effect of exogenous iodide ingestion, or, very rarely, struma ovarii, hydatidiform mole, or metastatic functioning follicular carcinoma of the thyroid.Recent descriptions of this form of thvroiditis deserve wider recognition, for these patients do not require the usual definitive forms of treatment for this disease-the hyperthyroidism seems to be transient.A short course of propranolol may be enough to tide the patient over the transient hyperthyroid state, and little more needs to be done apart from careful follow-up to detect possible hypothyroidism.
JAMA Journal Club
Journal: JAMA (1995)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Francis Home (1719-1813) Practitioner of Experimental Medicine
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Third Chronological Supplement to the Carcinogenic Potency Database: Standardized Results of Animal Bioassays Published through December 1986 and by the National Toxicology Program through June 1987
Authors: Lois Swirsky Gold, Thomas H. Slone, Georganne M. Backman, Susan Eisenberg, Maria Da Costa, Michael Wong, Neela B. Manley, Lars Rohrbach, Bruce N. Ames
Journal: Environmental Health Perspectives (1990)

This paper is the third chronological supplement to the Carcinogenic Potency Database that first appeared in this journal in 1984. We report here results of carcinogenesis bioassays published in the general literature between January 1985 and December 1986, and in Technical Reports of the National Toxicology Program between June 1986 and June 1987. This supplement includes results of 337 long-term, chronic experiments of 121 compounds, and reports the same information about each experiment in the same plot format as the earlier papers, e.g., the species and strain of animal, the route and duration of compound administration, dose level, and other aspects of experimental protocol, histopathology, and tumor incidence, TD50 (carcinogenic potency) and its statistical significance, dose response, opinion of the author about carcinogenicity, and literature citation. The reader needs to refer to the 1984 publication for a guide to the plot of the database, a complete description of the numerical index of carcinogenic potency, and a discussion of the sources of data, the rationale for the inclusion of particular experiments and particular target sites, and the conventions adopted in summarizing the literature. The four plots of the database are to be used together as results published earlier are not repeated. In all, the four plots include results for approximately 4000 experiments on 1050 chemicals. Appendix 14 of this paper is an alphabetical index to all chemicals in the database and indicates which plot(s) each chemical appears in. A combined plot of all results from the four separate papers, that is ordered alphabetically by chemical, is available from the first author, in printed form or on computer tape or diskette.
On the nature and ethics of phase I clinical trials of cancer chemotherapies
Authors: M. B. Lipsett
Journal: JAMA (1982)

PHYSICIANS and members of the public understand that each new drug must, at some point, be given to humans for the first time without confident knowledge of its effects and toxic potential. Although the ethics and constraints necessary for this testing have been discussed widely, there has been little attention given specifically to the first trials of new cancer chemotherapeutic agents (phase I trials). However, new cancer chemotherapeutic agents cannot be treated simply as new drugs; their toxic effects are often so much greater than those of other drugs that the clinical investigator must weigh many conflicting arguments to justify the trial. Referring physicians, in their role as advisors, are often called on to explain the trials and to counsel patients who may enter them. Thus, they should have full appreciation of the nature and ethics of such trials. A phase I clinical trial in patients with cancer does not
Compelled Medical Treatment of Pregnant Women-Reply
Authors: Lawrence J. Nelson
Journal: JAMA (1989)

<h3>In Reply.—</h3> I have two observations about Mr Ruley's letter. First, it demonstrates that the common law of England and America does not have a content that all courts and commentators agree on. Blackstone, one commentator on the common law, believed that the killing of a quick fetus was homicide at common law. The accuracy of this claim has been disputed by other authorities.<sup>1</sup>Modern American courts simply do not agree with Mr Ruley's view of the common law, and he has not produced a single one that does. These courts, and not Blackstone, define the current interpretation of the common law in this country. Mr Ruley obviously disagrees with these courts (as he is free to do), but he is the one in error as he attempts to ignore or downplay the significance or uniformity of the position they have adopted on this subject. I must add that
Establishment of murine model of acute-on-chronic liver failure
Authors: Nidhi Nautiyal, Deepanshu Maheshwari, Dhananjay Kumar, Rekha Kumari, Anupama Parasar, Chhagan Bihari, Subhrajit Biswas, Archana Rastogi, Rakhi Maiwall, Anupam Kumar, Shiv Kumar Sarin
Journal: Journal of Hepatology (2020)
Interindividual Variation in Carcinogen Metabolism and Bladder Cancer Risk
Authors: Paolo Vineis, Guglielmo Ronco
Journal: Environmental Health Perspectives (1992)

Epidemiological studies indicate that subjects of the genetically based slow acetylator phenotype may be at higher risk for bladder cancer than fast acetylators, particularly when they are exposed to carcinogenic arylamines: N-acetylation is a detoxification step in the metabolism of some arylamines. We describe two collaborative studies on tobacco smoking, in which markers of internal dose (arylamine-hemoglobin adducts) and markers of genetically-based metabolic polymorphism have been coupled. In the first investigation, we found that hemoglobin adducts formed by mononuclear arylamines have high reciprocal correlation coefficients, as do adducts from binuclear arylamines. This tendency of adducts with structurally similar arylamines to correlate reciprocally explains a large proportion of the residual variance seen after controlling for smoking habits (number and type of cigarettes). In the second study, the concentration of 4-amino-biphenyl-hemoglobin adducts varied according to three independent determinants: number of cigarettes, type of tobacco (air or flue cured), and acetylator phenotype (slow and fast). The dose-response relationship between the amount of tobacco smoked and level of 4-aminobiphenyl-hemoglobin adducts in the slow acetylators (with an immediate steep increase of the adducts) was different from that in the fast acetylators (with a more regular increase). These findings from "molecular epidemiology" may contribute to an understanding of the role of metabolic polymorphism in human carcinogenesis.
Afebrile Septicemia
Authors: Ian M. Smith
Journal: JAMA (1982)

Septicemia<sup>1</sup>is a silent killer. The absence of fever in the elderly (aged 65 years and older) in whom 42% of cases of septicemia and 6296 of the related deaths occur,<sup>2</sup>makes septicemia particularly difficult to diagnose (see p 1478 in this issue ofThe Journal). Without careful antibiotic therapy, recovery is rare in this life-threatening disease. After myocardial infarction, septicemia is the most frequent cause of death in the elderly, aged 70 years and older,<sup>3</sup>provided that all types of cancer are listed separately. In Europe, the term<i>bacteremia</i>indicates the temporary asymptomatic presence of bacteria in the blood and<i>septicemia</i>is the disease caused by established bacteremia. In the United States, the word<i>bacteremia</i>is used for both. I prefer the European nonmenclature, as it parallels bacteriuria and cystitis or pyelonephritis. The disease is often iatrogenic and hospital- or nursinghome—acquired; thus, physicians should be aware
Une incidence importante de néoplasie avancée colorectale lors de la surveillance endoscopique de la polypose festonnée
Journal: Endoscopy (2019)

La polypose festonnée (PF) est une entité définie par l’OMS comme: la présence d'au moins 5 lésions festonnées situées en amont du côlon sigmoïde dont au moins 2 sont supérieures à 10 mm (critère I), la présence d'au moins une lésion festonnée en amont du côlon sigmoïde chez un patient présentant un parent au premier degré atteint de PF (critère II) ou plus de 20 lésions festonnées réparties sur l’ensemble du côlon (critère III). Une surveillance annuelle par coloscopie est recommandée.